Search clinical trials for: Anti-Retroviral Agents

Total 189232 results

David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection (VIRECURE)

HIV Infections

Spain
National Institute of Allergy and Infectious Diseases...
Community Programs for Clinical Research on AIDS

Completed

Effects of Two Anti-HIV Drug Regimens on Quality of Life and Health Care Use Among SMART Study Participants

HIV Infections

United States
Viriom

Completed

An Open-label Clinical Study of the Pharmacokinetics and Safety of Elsulfavirine, 200 mg Tablets, With Single and Multiple Oral Administration in Healthy Volunteers

Covid19 | HIV-1-infection

Russian Federation
Genzyme, a Sanofi Company
Sanofi

Completed

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Neuroblastoma | Brain Tumors | Ewing's Sarcoma/Soft Tissue Sarcoma

Belgium, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Spain, United Kingdom
Mitchell Horwitz, MD
Genzyme, a Sanofi Company

Completed

Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant

Failure of Bone Marrow Graft

United States
University of Padova
Azienda Ospedaliera di Padova

Completed

Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects

Diabetes

Italy
University Hospital, Clermont-Ferrand

Completed

Mobilization by Plerixafor of Haematopoietic Stem Cells in Children (MEP1)

Children Cancer, Solid Tumor

France
Emory University

Terminated

AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia (BMTAMD3100)

Pediatric Acute Myeloblastic Leukemia, Relapsed | Pediatric Acute Lymphoblastic Leukemia, Relapsed

United States
St. Jude Children's Research Hospital
Doris Duke Charitable Foundation

Withdrawn

Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor

Sickle Cell Disease

United States
Viriom

Completed

Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects

HIV-1-infection

United States
Assistance Publique - Hôpitaux de Paris
EuroFancolen

Completed

Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor (FancoMob)

Fanconi Anemia

France
ViiV Healthcare
GlaxoSmithKline

Completed

Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Relative Bioavailability Study With BMS-955176

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

Food Effect Study With BMS-955176

Infection, Human Immunodeficiency Virus

United Kingdom
International Partnership for Microbicides, Inc.

Completed

Expanded Use PK of Dapivirine Vaginal Ring

Pharmacokinetics
Genzyme, a Sanofi Company

No longer available

This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. (EAP)

Multiple Myeloma | Non-Hodgkin's Lymphoma | Hodgkin's Disease
Emory University
Genzyme, a Sanofi Company

Completed

Alteration in Timing of Plerixafor Administration

Autologous Transplantation

United States
Tanox

Unknown

TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1

HIV Infections

United States, Puerto Rico, Canada
University of Washington
National Institute of Mental Health (NIMH)

Recruiting

HeadStART: Evaluating the Effectiveness of Community ART Delivery for People Newly Diagnosed With HIV (HeadStART)

HIV Infections | Hiv

Uganda
National Institute of Allergy and Infectious Diseases...

Recruiting

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

Multi-Drug Resistant Hiv-1 Infection | HIV-1 Infection

United States
Peking Union Medical College Hospital

Completed

Gut Microbiota Changes of HIV Patients Before and After One Year of ART

HIV Infections

China
Duke University
Janssen, LP

Completed

Obesity in HIV After Antiretroviral Therapy

Obesity | HIV | AIDS

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

Infections | Warts | Neutropenia | Leukopenia | Myelokathexis

United States
Ensoma
bluebird bio

Terminated

Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

Sickle Cell Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults

HIV Infections

United States
Hospital Universitari Vall d'Hebron Research Institute
CIEMAT; CIBERER

Completed

Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1

Fanconi Anemia

Spain
Tufts Medical Center

Terminated

Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation

Lymphoma | Multiple Myeloma | Chronic Lymphocytic Leukemia

United States
Genzyme, a Sanofi Company

Completed

A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). (PREDICT)

Transplantation | Lymphoma (Non-Hodgkin's Lymphoma) | Hodgkin's Disease or Multiple Myeloma | Front Line Mobilization

Netherlands, France, Germany, Sweden, Spain, Italy, United Kingdom
Genzyme, a Sanofi Company

Completed

A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent

Healthy Volunteer

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

Prospective Observational Study on Plerixafor After Chemotherapy

Lymphoma | Myeloma

Italy
International Partnership for Microbicides, Inc.

Withdrawn

A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa

HIV Infections

South Africa, Malawi, Rwanda, Zimbabwe
Shi, Patricia, M.D.
Genzyme, a Sanofi Company

Unknown

Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection

Multiple Myeloma | Non-Hodgkins Lymphoma

United States
International Partnership for Microbicides, Inc.

Completed

An Expanded Safety Study of Dapivirine Gel 4759 in Africa

HIV Infections | Acquired Immunodeficiency Syndrome

Kenya, Malawi, Rwanda, South Africa, Tanzania
International Partnership for Microbicides, Inc.

Completed

A Safety Study to Assess the Delivery of Dapivirine From a Matrix Vaginal Ring

HIV Infections

Belgium
Sarawak MediChem Pharmaceuticals

Completed

A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment

HIV Infections

United States
Hugh Taylor

Recruiting

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

Asherman Syndrome | Recurrent Implantation Failure | Atrophic Endometrium

United States
The Methodist Hospital Research Institute

Completed

Low Dose IL2 Immunotherapy in AD

Alzheimer Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

HIV Infections

Argentina
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children

HIV Infections

United States
Chiron Corporation

Completed

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis

HIV Infections | Cytomegalovirus Retinitis

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effect of Interleukin-2 on HIV Treatment Interruption

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy

HIV Infections

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy

HIV Infections

United States
National Cancer Institute (NCI)

Completed

Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer

Metastatic Melanoma | Renal Cell Cancer

United States
Chiron Corporation

Unknown

Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy

HIV Infections

United States
Chiron Corporation

Completed

A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients

HIV Infections

United States
University of Minnesota
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Understanding the Increased Risk of Cardiovascular Disease in People With HIV

HIV Infections
University of Minnesota
National Health and Medical Research Council, Australia; Bristol-Myers Squibb; National Institutes of Health Clinical Center (CC) and other collaborators

Completed

Strategic Timing of Antiretroviral Treatment (START)

HIV Infection

Spain, United States, United Kingdom, Ireland, Australia, Argentina, Denmark, Sweden, Israel, Switzerland, Germany, Brazil, Norway, Chile, Thailand, Peru, Portugal, Greece, Luxembourg, Uganda, Austria, Belgium, Czechia, Estonia, Finland, ... and more
United BioPharma

Completed

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

HIV-1 Infection

Taiwan
University of California, Los Angeles
Tulane University; Los Angeles LGBT Center

Active, not recruiting

Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection

Human Immunodeficiency Virus

United States

Search clinical trials for: Anti-Retroviral Agents

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations